Equity Overview
Price & Market Data
Price: $2.09
Daily Change: +$0.04 / 1.91%
Range: $2.05 - $2.12
Market Cap: $148,301,376
Volume: 351,722
Performance Metrics
1 Week: -0.95%
1 Month: 9.42%
3 Months: -10.68%
6 Months: -38.71%
1 Year: -68.71%
YTD: -16.06%
Company Details
Employees: 157
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.